Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Midcap 150 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark Pharmaceuticals has submitted its financial results to the stock exchange for the period ending March 31, 2025. This typically covers the fourth quarter and full financial year FY25 results. The filing itself is a routine compliance disclosure notifying the exchange that the results have been filed; the detailed financial figures would be available in the accompanying results document. No specific numbers, revenue figures, or profit data are included in this announcement text itself.
This is a routine regulatory filing and does not by itself move the stock. Investors should review the detailed results document for actual revenue, profit, margin, and guidance figures to assess the company's FY25 performance.